Since brain imaging is essential to the diagnostic assessment of Stage IV NSCLC, a specific examination focused on the eyes should be recommended, particularly when EGFR-mutant lung cancer patients experience visual symptoms, such as visual disturbance. This evidence concerns the gene EGFR and lung carcinoma.